Evidence map›Paper›PMID 31251436›Full record

ArticleMovement disorders : official journal of the Movement Disorder Society2019

Evolution and clustering of prodromal parkinsonian features in GBA1 carriers.

Stephen Mullin, Michelle Beavan, Jonathan Bestwick, Alisdair McNeill, Christos Proukakis, Timothy Cox, Derralynn Hughes, Atul Mehta, Henrik Zetterberg, Anthony H V Schapira

Open access · hybridAbstract read
In one paragraph

Article in Movement disorders : official journal of the Movement Disorder Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Phenotypic consequences of GBA1 pathological variant R463C (p.R502C).American journal of medical genetics. Part A · 2024
    Article
  6. Review
  7. Article
  8. Article
  9. Clinical prediction ofClinical parkinsonism & related disorders · 2024
    Article
  10. Review
  11. International journal of molecular sciences · 2023
    Review
  12. The pathobiological basis of depression in Parkinson disease: challenges and outlooks.Journal of neural transmission (Vienna, Austria : 1996) · 2022
    Review
  13. Review
  14. GBA-associated PD: chances and obstacles for targeted treatment strategies.Journal of neural transmission (Vienna, Austria : 1996) · 2022
    Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Behavioral Phenotyping in a Murine Model ofInternational journal of molecular sciences · 2021
    Article
  20. Profiling the Biochemical Signature of GBA-Related Parkinson's Disease in Peripheral Blood Mononuclear Cells.Movement disorders : official journal of the Movement Disorder Society · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 4 countries.

Stephen MullinDepartment of Clinical and Movement Neurosciences, University College London Queen Square Institute of Neurology, London, United Kingdom.
Michelle BeavanDepartment of Clinical and Movement Neurosciences, University College London Queen Square Institute of Neurology, London, United Kingdom.
Jonathan BestwickWolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
Alisdair McNeillSheffield Institute of Translational Neuroscience, University of Sheffield, Cambridge, United Kingdom.
Christos ProukakisDepartment of Clinical and Movement Neurosciences, University College London Queen Square Institute of Neurology, London, United Kingdom.
Timothy CoxDepartment of Medicine, University of Cambridge, Cambridge, United Kingdom.
Derralynn HughesLysosomal Storage Disorders Unit, Royal Free Hospital, Royal Free London NHS Foundation Trust, and Department of Haematology, University College London, London, United Kingdom.
Atul MehtaLysosomal Storage Disorders Unit, Royal Free Hospital, Royal Free London NHS Foundation Trust, and Department of Haematology, University College London, London, United Kingdom.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Anthony H V SchapiraDepartment of Clinical and Movement Neurosciences, University College London Queen Square Institute of Neurology, London, United Kingdom.
National Hospital for Neurology and Neurosurgery · GBRoyal Free London NHS Foundation Trust · GBUniversity College London · GBCambridge School · PTQueen Mary University of London · GBUniversity of Sheffield · GB

Funding

Medical Research Council MR/K015338/1Medical Research Council MR/M006646/1Medical Research Council MR/N028651/1Wellcome Trust WT089698/Z/09/Z
6 · The paper itself

Abstract

backgroundFive to 25% of patients with PD carry glucocerebrosidase gene mutations, and 10% to 30% of glucocerebrosidase carriers will develop PD by age 80. Stratification of PD risk in glucocerebrosidase carriers provides an opportunity to target disease-modifying therapies.

objectiveCross-sectional and longitudinal survey of prodromal PD signs among glucocerebrosidase carriers.

designProspective assessment of 82 glucocerebrosidase mutation carriers and 35 controls over 4 to 5 years for prodromal clinical PD features.

resultsAt all time points, olfactory (measured using University of Pennsylvania Smell Identification Test) and cognitive (Montreal Cognitive Assessment) function and the International Parkinson and Movement Disorder Society UPDRS parts II and III scores were significantly worse amongst glucocerebrosidase mutation carriers. Progression to microsmia (odds ratio: 8.5; 95% confidence interval: 2.6-28.2; P < 0.05) and mild cognitive impairment (odds ratio: 4.2; 95% confidence interval: 1.1-16.6; P < 0.05) were more rapid compared to controls. Those with worse olfaction also had worse cognition (OR, 1.5; 95% CI: 0.0-2.8; P < 0.05) and depression (OR, 1.3; 95% CI: 0.6-2.8; P < 0.05). No participants reached the MDS prodromal PD diagnostic criteria before PD diagnosis. One participant developed PD. He did not fulfill the International Parkinson and Movement Disorder Society prodromal PD criteria before diagnosis.

conclusionAssessment of individual and clustered PD prodromal features may serve as a useful tool to identify high-risk subjects for conversion to PD. As a result of the low conversion rate in our glucocerebrosidase mutation carriers to date, prospective validation is needed in larger cohorts to establish the profile of these features in PD convertors. © 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Indexed as

Prodromal SymptomsAdultAgedCluster AnalysisCross-Sectional StudiesDisease ProgressionFemaleGenotypeGlucosylceramidaseHeterozygoteHumansMaleMiddle AgedMutationParkinsonian DisordersProspective StudiesGBA protein, humanGlucosylceramidasecognitiondepressionGaucherglucocerebrosidaseolfactionParkinson'sprodromal

Identifiers

PMID31251436
PMCPMC6790937
OpenAlexW2955208925

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.